Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
Top Cited Papers
- 10 May 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (19), 1915-1927
- https://doi.org/10.1056/nejmoa061741
Abstract
Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated with HPV-16 and HPV-18.Keywords
This publication has 31 references indexed in Scilit:
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countriesVaccine, 2006
- Chapter 5: Updating the natural history of HPV and anogenital cancerVaccine, 2006
- Oncogenic Human Papillomavirus DNA Loads in Human Immunodeficiency Virus-Positive Women with High-Grade Cervical Lesions Are Strongly ElevatedJournal of Clinical Microbiology, 2003
- Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significanceAmerican Journal of Obstetrics and Gynecology, 2003
- A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretationsAmerican Journal of Obstetrics and Gynecology, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Concurrent and Sequential Acquisition of Different Genital Human Papillomavirus TypesThe Journal of Infectious Diseases, 2000
- FIGO staging classifications and clinical practice gudelines in the management of gynecologic cancersInternational Journal of Gynecology & Obstetrics, 2000
- Exact power and sample size for vaccine efficacy studiesCommunications in Statistics - Theory and Methods, 1998